![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 40, 37331-37338, October 4, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Biochemical Sciences, University of Florence, 50134 Florence, Italy
Received for publication, May 28, 2002, and in revised form, July 15, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Low molecular weight phosphotyrosine phosphatase
(LMW-PTP) is an enzyme involved in platelet-derived growth
factor-induced mitogenesis and cytoskeleton rearrangement. Our previous
results demonstrated that LMW-PTP is able to bind and dephosphorylate activated platelet-derived growth factor receptor (PDGF-r), thus inhibiting cell proliferation. Here we revisit the role of LMW-PTP on
activated PDGF-r dephosphorylation. We demonstrate that LMW-PTP preferentially acts on cell surface PDGF-r, excluding the internalized activated receptor pool. Many phosphotyrosine phosphatases act by site-selective dephosphorylation on several sites of PDGF-r, but
until now, there has been no evidence of a direct involvement of a
specific phosphotyrosine phosphatase in the dephosphorylation of the
857 kinase domain activation tyrosine. Here we report that LMW-PTP
affects the kinase activity of the receptor through the binding and
dephosphorylation of Tyr-857 and influences many of the signal
outputs from the receptor. In particular, we demonstrate a
down-regulation of phosphatidylinositol 3-kinase, Src homology phosphatase-2, and phospholipase C- Although PDGF1 plays an
important role in normal development, accumulating evidence suggests
that its abnormal expression also contributes to a variety of diseases.
This is emphasized by the fact that PDGF and its receptor are currently
under investigation as targets in numerous proliferative disorders,
including cancer and cardiovascular and fibrotic diseases (1). Binding
of PDGF to the extracellular domain of the receptor is thought to
induce receptor dimerization, allowing transphosphorylation of adjacent dimerized receptors on specific tyrosine residues within the
intracellular region (2). The phosphorylated tyrosines supply docking
sites for recruitment of cytosolic signaling proteins with
appropriate binding motifs. The cellular function of
receptor-associated proteins is believed to be modified as a
consequence of association with and phosphorylation by the receptor
itself. Thus, ligand binding initiates intracellular signaling events
involving the synthesis of second messenger molecules, activation of
small G proteins, protein phosphorylation cascades, and, finally, gene
transcription. All these signaling pathways are thought to mediate
biological responses to PDGF through cell cycle progression (3). The
systems used to fine-tune receptor-induced signaling and the full
variety of the signaling potential of the receptor remain uncertain. It has been demonstrated that PDGF-r expression is down-regulated for the
duration of the second phase of the cell cycle and during cell
differentiation. In particular, PDGF-r down-regulation appears to be
regulated at two stages: a short time level, which is thought to be
played essentially by an immediate endocytosis of
ligand-receptor complexes, and a long-term down-regulation reply,
played by receptor degradation by ubiquitin-dependent
proteolysis (4) and by decline of PDGF It is well established that receptor tyrosine kinases are negatively
controlled by phosphotyrosine phosphatases (PTPs) (5, 6).
Down-regulation of tyrosine kinase receptors by PTPs could be a more
rapid system with respect to the elimination of activatable PDGF-r from the membrane by clathrin-mediated internalization and the
decrease of PDGF-r molecules by ubiquitin-mediated or lysosomal
proteolysis or mRNA repression (7). There is little in the
literature about the role of PDGF-r dephosphorylation by PTPs, although
many PTPs have been found to interact with the receptor. In particular,
SHP-2 (8), density-enhanced phosphatase-1 (9), LMW-PTP (10), and
CD45 (11) have been depicted to dephosphorylate the
activated PDGF-r, although the real significance of this
dephosphorylation is largely unclear. In fact, PTP action on tyrosine
kinase receptors could lead either to a broad reduction of receptor
signaling, by targeting to all receptor phosphotyrosines, or to a
modulation of signaling, through site-selective dephosphorylation.
LMW-PTPs are a group of 18-kDa enzymes that are widely expressed (12).
Previous studies on the molecular biology of LMW-PTP in NIH3T3 cells
demonstrated a well-defined role of this enzyme in PDGF-induced
mitogenesis, showing that activated PDGF-r is a substrate for LMW-PTP
(10, 13). The most relevant phenotypic effect of LMW-PTP overexpression
is a strong reduction of the cell growth rate in response to PDGF
stimulation. More recently, we have found that in NIH3T3 cells, LMW-PTP
is constitutively localized in both cytoplasmic and
cytoskeleton-associated fractions. These two LMW-PTP pools are
differentially regulated because only the cytoskeleton-associated
LMW-PTP fraction is specifically phosphorylated by c-Src after PDGF
stimulation (13, 14). Cytoskeleton-associated LMW-PTP influences cell
adhesion, spreading, and migration, controlling the phosphorylation
level of p190Rho-GAP, a protein that is able to regulate Rho activity
and, consequently, cytoskeleton rearrangement in response to PDGF
stimulation. Hence, LMW-PTP is able to perform multiple functions in
PDGF-induced mitogenesis: whereas cytosolic LMW-PTP binds and
dephosphorylates PDGF-r, thus modulating part of its signaling cascade,
cytoskeleton-associated LMW-PTP acts on phosphorylated p190Rho-GAP,
consequently playing a role in PDGF-mediated cytoskeleton rearrangement
(15). Recently, we demonstrated that during PDGF signaling, LMW-PTP is
regulated by a redox mechanism involving the two cysteine residues of
the catalytic site, which turn reversibly from the reduced to oxidized state after PDGF stimulation. The reversibility of in vivo
LMW-PTP oxidation is glutathione-dependent (12). The
additional catalytic pocket Cys-17 retains an intriguing and peculiar
role in the formation of a S-S intramolecular bond, which protects the
catalytic Cys-12 from further and irreversible oxidation. The presence
of an additional cysteine near the catalytic one confers upon LMW-PTP
the ability to rapidly recover its activity and finely regulate PDGF
receptor activation.
In this study, we revisit the role of LMW-PTP in PDGF-r
down-regulation, demonstrating that it acts as a real termination signal for receptor activation because it dephosphorylates the PDGF-r-regulatory tyrosine (Tyr-857), thus determining a general negative regulation of all downstream signals, with the exception of
those elicited by internalized receptors.
Materials--
Unless specified, all reagents were obtained from
Sigma. NIH3T3 cells were purchased from American Type Culture
Collection, and HepG2 cells expressing wild-type PDGF-r or Y857F mutant
PDGF-r were a generous gift of Dr. A. Kazlauskas and have been
described elsewhere (16). Human recombinant PDGF-BB was from Peprotech, and the Enhanced Chemiluminescence kit was from Amersham Biosciences. All antibodies were from Santa Cruz Biotechnology, with the
exception of those against Tyr(P)-716 and p85-PI3K, which were from
Upstate Biotechnology Inc. Antibodies against Tyr(P)-751 and Tyr(P)-857 were a generous gift of Dr. A. Kazlauskas and have been described elsewhere (17). BCA protein assay reagent was from Pierce.
Dichlorodihydrofluorescein diacetate (DCFDA) was obtained from
Molecular Probes.
Cell Culture and Transfections--
NIH3T3 or HepG2 cells were
routinely cultured in Dulbecco's modified Eagle's medium supplemented
with 10% fetal calf serum in a 5% CO2 humidified
atmosphere. 10 µg of pRcCMV-C12S-LMW-PTP (expressing the dominant
negative Cys-12 to Ser mutant of LMW-PTP) were transfected in NIH3T3
cells using the calcium phosphate method. Stable transfected clonal
cell lines were isolated by selection with G418 (400 µg/ml).
Mock-transfected cell lines were obtained by transfecting 2 µg of
pRcCMVneo alone. The clonal cell lines were screened for expression of
the transfected genes by (a) Northern blot analysis and
(b) enzyme-linked immunosorbent assay using polyclonal
anti-LMW-PTP rabbit antibodies.
Immunoprecipitation and Western Blot Analysis--
1 × 106 cells were seeded in 10-cm plates in Dulbecco's
modified Eagle's medium supplemented with 10% fetal calf serum. Cells were serum-starved for 24 h before receiving 30 ng/ml PDGF-BB. Cells were then lysed for 20 min on ice in 500 µl of radioimmune precipitation assay buffer lysis buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1%
Nonidet P-40, 2 mM EGTA, 1 mM sodium
orthovanadate, 1 mM phenylmethanesulfonyl fluoride, 10 µg/ml aprotinin, and 10 µg/ml leupeptin). Lysates were clarified by
centrifugation and immunoprecipitated for 4 h at 4 °C with 1-2
µg of the specific antibodies. Immunocomplexes were collected on
protein A-Sepharose (Amersham Biosciences), separated by SDS-PAGE, and
transferred onto nitrocellulose (Sartorius). Immunoblots were incubated
in 3% bovine serum albumin, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 0.1% Tween 20 for 1 h at room
temperature, probed with specific antibodies and then with secondary
antibodies conjugated with horseradish peroxidase, washed, and
developed with the Enhanced Chemiluminescence kit.
PDGF-r Internalization by Trypsinization--
PDGF-r
internalization was determined by measuring the percentage of receptors
that were resistant to trypsinization according to Ceresa
et al. (18). Briefly, cells were serum-starved for 24 h
and then stimulated with 30 ng/ml PDGF-BB. The cells were washed twice
with phosphate-buffered saline and incubated on ice for 8 min with
ice-cold, 20 mM sodium acetate, pH 3.7. The cells were
washed with ice-cold phosphate-buffered saline and incubated with
trypsin (1 mg/ml in phosphate-buffered saline) in ice for 30 min with
occasional rocking. The reaction was stopped by the addition of soybean
trypsin inhibitor (1 mg/ml). Cells were then washed and solubilized in
lysis buffer for 10 min at 4 °C. The cell lysates were
immunoprecipitated with anti-PDGF-r antibodies and subjected to
SDS-PAGE. The trypsin-resistant 190-kDa PDGF-r is the
internalized receptor. The total PDGF-r amount was evaluated in
parallel in non-trypsinized cells.
PDGF-r Kinase Activity Assay--
Cell lysates in lysis buffer
were subjected to immunoprecipitation with anti-PDGF-r subunit
antibodies (Santa Cruz Biotechnology). The immunoprecipitated proteins
were washed twice in lysis buffer, washed twice in 50 mM
Tris-HCl, pH 7.4, containing 1 mM sodium orthovanadate, and
finally resuspended in 50 mM Hepes, pH 7.4, 10 mM MnCl2. The reaction was started with the
addition of [32P]ATP (3000 Ci/mmol, 20 µCi) to all
samples, which were incubated at 4 °C for 10 min. The beads were
then washed once with 50 mM Tris-HCl, pH 7.4, and finally
resuspended in 20 µl of Laemmli's sample buffer, boiled for 5 min,
and separated by 7.5% SDS-PAGE (19). The autoradiogram was
scanned using Chemidoc Quantity One software (Bio-Rad).
Normalization was achieved by anti-PDGF-r immunoblot of a part of the
analyzed samples. In addition, the PDGF-r kinase activity was assayed
using an exogenous substrate, glutathione
S-transferase-PLC- Phosphatidylinositol 3-Kinase Assay--
The PI3K assay was
performed as described elsewhere (20). Briefly, serum-starved cells
were incubated with 30 ng/ml PDGF for 10 min and then lysed in
radioimmune precipitation assay buffer. Equal amounts of proteins were
immunoprecipitated using PY20 anti-phosphotyrosine antibody (Santa Cruz
Biotechnology). After washing, the immunobeads were resuspended in 50 µl of 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, and 0.5 mM EGTA. 0.5 µl of 20 mg/ml phosphatidylinositol
was added, mixed, and incubated at 25 °C for 10 min. 1 µl of 1 mM MgCl2 and 10 µCi of [32P]ATP
(3000 Ci/mmol) were then added simultaneously and incubated at 25 °C
for an additional 10 min. The reaction was stopped by the addition of
150 µl of chloroform, methanol, and 37% HCl (10:20:0.2). The samples
were extracted with chloroform and dried. Radioactive lipids were
separated by thin-layer chromatography using chloroform, methanol, 30%
ammonium hydroxide, and water (46:41:5:8). After drying, the plates
were autoradiographed. The radioactive spots corresponding to
phosphatidylinositol phosphate were scraped and counted in a liquid
scintillation counter.
MAPK Activation--
1.5 × 104 cells were
plated on a 6-well dish in complete medium. Cells were serum-starved
for 24 h before receiving 30 ng/ml PDGF-BB for the indicated
times, lysed in radioimmune precipitation assay buffer, and
centrifuged to remove the insoluble debris. The total protein content
was evaluated by the BCA protein assay, and 20 µg of lysates were
resolved on a 12% SDS-PAGE. The resolved proteins were transferred to
nitrocellulose membrane and probed overnight with
anti-phospho-extracellular signal-regulated kinase 1/2 monoclonal antibodies.
LMW-PTP/PDGF-r in Vitro Binding Assay--
The binding assay was
performed as described elsewhere (21). Briefly, after PDGF-BB
stimulation, HepG2 cells expressing wild-type or the Tyr to Phe mutant
version of PDGF-r were lysed, and PDGF-r was immunoprecipitated.
Immunocomplexes were collected as usual with protein A-Sepharose and
washed several times with radioimmune precipitation assay buffer and
once with binding buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM MgCl2, 100 mM NaCl, and 0.1% Triton X-100). Agarose-bound receptors
were resuspended in 0.1 ml of binding buffer and allowed to associate
with 1 µg of dominant negative glutathione
S-transferase-LMW-PTP at 4 °C for 1 h. The beads
were washed twice in 1 ml of binding buffer and resuspended in SDS-PAGE
sample buffer for anti-LMW-PTP immunoblot analysis.
LMW-PTP Controls the Tyrosine Phosphorylation Level of
PDGF-r--
Previous studies have shown that in NIH3T3 cells,
overexpression of dnLMW-PTP causes an increased mitogenic response to
PDGF, whereas overexpression of the wild-type LMW-PTP has the opposite effect (10, 23). The dominant negative form of LMW-PTP is a mutant of
the catalytic site Cys-12 to Ser. As in all PTPs, the catalytic site
cysteine is capable of transiently forming the
cysteinyl-phosphate intermediate, and the mutation of this amino acid
residue converts the enzyme in an inactive phosphatase. The
preservation of the substrate binding site(s) in the C12S mutant
(i.e. the Arg residue in the catalytic pocket) maintains the
potential to bind intracellular natural substrates, leading to
the increase in their tyrosine phosphorylation level. Here we perform a
time course experiment (Fig.
1A) in which cells
overexpressing dnLMW-PTP were serum-starved for 24 h and
stimulated with PDGF for 10, 45, and 120 min. The tyrosine
phosphorylation level of PDGF-r was evaluated by anti-phosphotyrosine
immunoblot, in comparison with mock-transfected cells. The blot has
been reprobed with anti-PDGF-r antibodies for normalization (Fig.
1B). The results, shown in Fig. 1A, demonstrated
that overexpression of dnLMW-PTP leads to a great increase in the
tyrosine phosphorylation level of the activated receptor. Notably, we
observe an increase in both the peak of PDGF-r tyrosine phosphorylation
(10 min) and the duration of activation of the receptor itself (Fig.
1C). Hence, overexpression of dnLMW-PTP produces a dramatic
effect on the activation of PDGF-r, leading to a greater and longer
activation with respect to mock-transfected cells.
LMW-PTP Does Not Affect the Tyrosine Phosphorylation Level of
Internalized PDGF-r--
The internalization and trafficking of
ligand-activated cell surface receptor have long been reported as a
possible down-regulation mechanism for many receptors (24). In
addition, it has been reported recently that endosomes retain a role in
either initiating or extending the signal elicited at the plasma
membrane, namely, MAPK pathway activation (25-27). We analyzed the
tyrosine phosphorylation level of internalized PDGF-r by trypsin
treatment of agonist-stimulated dnLMW-PTP-overexpressing cells in
comparison with mock-transfected ones. This method allows a direct
analysis of receptor endocytosis by means of trypsin-directed
proteolysis of the cell surface receptor. The internalized receptors
are in fact the only ones retaining the original molecular weight,
whereas the receptor molecules remaining at the cell surface are
cleaved by trypsin. Our results (Fig.
2A) indicate that receptor
internalization shows similar kinetics in both dnLMW-PTP-overexpressing
cells and mock-transfected cells, with a maximum at 10 min after
stimulation, followed by a slow decrease. The data have been normalized
on the basis of anti-PDGF-r immunoblot by stripping and reprobing the
same filter (Fig. 2B) and plotting the values in Fig.
2C. The results indicate that LMW-PTP does not affect
the tyrosine phosphorylation level of the internalized receptor and
that the tyrosine phosphorylation level of the internalized receptor
does not decrease as rapidly as the cell surface receptor
phosphorylation level (Fig. 1) but remains high for at least 2 h.
LMW-PTP Binds and Dephosphorylates the Tyr-857 of PDGF-r, Thus
Influencing Receptor Kinase Activity--
The tyrosine phosphorylation
level of PDGF-r after stimulation is due to the regulation of the rate
of phosphorylation or dephosphorylation. It has been reported that in
PDGF-r, phosphorylation of the activation loop tyrosine in position 857 temporally precedes the complete autophosphorylation of the receptor in
multiple SH2 domain binding sites and is required for the full
activation of receptor kinase activity (16). To investigate the effect
of LMW-PTP on Tyr-857, we analyzed the binding of LMW-PTP to Tyr-857 after PDGF-r activation. We have already reported that LMW-PTP binds
only to agonist-activated PDGF-r through the phosphatase catalytic
site, although we had no information about the specific tyrosine(s)
involved in its binding (10, 13). HepG2 cells overexpressing the
wild-type PDGF
The requirement of phosphorylation in Tyr-857 for receptor tyrosine
kinase activity is well documented (29, 30). In this light, we assayed
PDGF-r autophosphorylation activity in cells overexpressing dnLMW-PTP
(Fig. 4A). PDGF-r kinase
activity on an exogenous substrate such as PLC- Analysis of the Tyrosine Phosphorylation level of PDGF-r
Sites--
To investigate the hypothetical site selectivity of LMW-PTP
in PDGF-r dephosphorylation, we analyzed the tyrosine phosphorylation level of different sites in a time course experiment with
mock-transfected and dnLMW-PTP-overexpressing cells. We stimulated
cells for the period necessary to commit cells to S-phase entry,
namely, 8-9 h (28). We used phosphospecific antibodies directed toward
Tyr(P)-857 (activation loop), Tyr(P)-751 (PI3K binding site),
Tyr(P)-716 (Grb2 binding site), and Tyr(P)-1021 (PLC-
Taken together, these data suggest that LMW-PTP acts as a general
PDGF-r signaling terminator by lowering the phosphorylation level of
the regulatory Tyr-857 and/or many of the phosphotyrosines that
mediated SH2-binding protein activation but not of the Grb2 binding
site Tyr-716.
Analysis of the PDGF-r Downstream Pathways Affected by
LMW-PTP--
The tyrosine phosphorylation of PDGF-r leads to the
recruitment of many SH2 domain-containing proteins. For many of them, different tyrosines have been found to be specific binding sites. In
particular PI3K binds to Tyr-751, PLC-
Taken together, these data indicate that LMW-PTP acts on PDGF-r
signaling, regulating many signal transduction pathways. The role of LMW-PTP in down-regulation of the activation of PI3K, SHP-2,
and PLC- The notion that PTPs act as negative regulators of receptor
tyrosine kinase signaling by direct dephosphorylation of receptor tyrosine kinases has received some experimental support. For example, overexpression of CD45 reduces PDGF receptor tyrosine phosphorylation (11), and antisense-mediated suppression of leukocyte common antigen-related (LAR) phosphatase potentiates signaling of
various growth factor receptors, including insulin and epidermal growth factor receptors (32). In addition, data for negative regulation of
epidermal growth factor receptor signaling by rPTP The aim of our work was to study the specific role of LMW-PTP in the
context of PDGF-r down-regulation by dephosphorylation. We state that
LMW-PTP greatly influences the activation of PDGF-r. In fact, the
overexpression of a dominant negative mutant of LMW-PTP induces a
dramatic increase in both the phosphorylation peak (10 min) and the
duration of phosphorylation. This effect explains the great increase we
observed in cell proliferation and G1 cell cycle phase
length in dnLMW-PTP-expressing cells (10, 13).
First, our findings indicate that LMW-PTP does not act on internalized
receptors because we show that this phosphatase does not influence the
tyrosine phosphorylation level of the internalized activated receptor
(Fig. 2). The internalization of the PDGF-r upon stimulation with the
agonist is one of the earliest responses elicited by PDGF. The
internalization is mediated by clathrin-coated pits in which the
100-kDa GTPase dynamin is responsible for the pinch-off step of the
vesicle. Internalized receptors can recycle back to the cell surface or
be sorted to lysosomal degradation (35). Many authors have reported
that ligand-induced internalization retains a specific role in signal
transduction, especially in MAPK activation. In fact, inhibition of
insulin receptor internalization leads to a partial inhibition of Shc
phosphorylation and MAPK down-regulation (18, 36, 37). These findings
indicate that the internalized insulin receptors have a positive signal
transduction role, at least in Shc and MAPK pathways. In addition,
Burke (25) has recently demonstrated that epidermal growth factor
signaling is positively regulated by endocytosis and intracellular
trafficking. It is likely that dephosphorylation of the internalized
receptor is not a mechanism of down-regulation of the selective
pathways activated by this subset of receptors. In fact, the
internalized receptor remains highly phosphorylated for very long
times, suggesting that this receptor is not a substrate for any PTPs,
as already reported (38), and not only for LMW-PTP. It has been
reported that down-regulation of MAPK activation is achieved by an
alternative route: activated p42 and p44 MAPKs are specifically and
directly dephosphorylated by MAPK phosphatases, a group of dual
specificity PTPs transcriptionally induced upon agonist treatment (39). In this context, the direct dephosphorylation of the internalized receptors could be a marginal phenomenon.
Furthermore, we demonstrate that LMW-PTP specifically binds and
dephosphorylates PDGF-r Tyr-857, affecting both the autophosphorylation activity of the receptor and its kinase activity toward exogenous substrates. Tyr-857 is one of the autophosphorylation sites of the
PDGF-r, is located in the kinase domain, and regulates the catalytic
activity of the receptor kinase (29, 40). We suggest that LMW-PTP
affects the kinase activity of the receptor within 10 min after
stimulation, dephosphorylating the kinase loop tyrosine. Later on,
LMW-PTP does not influence receptor tyrosine kinase activity any more,
in agreement with previous reports, suggesting that Tyr-857 is only
briefly phosphorylated (17, 41). We emphasize that LMW-PTP is, to date,
the only PTP able to dephosphorylate the activation loop regulatory
tyrosine, thus influencing the kinase activity of the receptor both
toward exogenous substrates and the receptor itself. In fact, only for
SHP-2 and density-enhanced phosphatase-1 has site selectivity has been
proven, although for both these phosphatases the Tyr-857 is not a
preferential dephosphorylation site (9, 34). 11 of the 15 tyrosine
residues outside the catalytic domain of PDGF-r (3) have been
demonstrated to undergo autophosphorylation after ligand stimulation.
We analyzed the role of LMW-PTP in the control of the tyrosine
phosphorylation level of some of these phosphotyrosines, namely,
Tyr(P)-857 (kinase activation loop), Tyr(P)-751 (PI3K binding site)
Tyr(P)-716 (Grb2 binding site), and Tyr(P)-1021 (PLC- The tyrosine phosphorylation level of any Tyr(P) site in PDGF-r could
be due to the regulation of the rate of phosphorylation or
dephosphorylation. We speculate that the LMW-PTP-dependent dephosphorylation of Tyr-857, which acts as the regulatory site of the
kinase activity of the receptor, could be responsible for all other
downstream effects, including the decreased tyrosine phosphorylation
level of signaling phosphotyrosines, although we could not exclude that
LMW-PTP partially affects the phosphorylation level of other tyrosines.
In fact, we observed a strongly reduced but not completely ablated
binding of LMW-PTP to the Y857F mutant PDGF-r.
In contrast, we report a very slight action of LMW-PTP on Tyr-716,
lower with respect to that against Tyr-857, Tyr-751, and Tyr-1021.
Tyr-716 directs the main route for MAPK activation through Grb2 binding
(42), although this pathway could be activated by Grb2-independent ways
(Fig. 5). Because the link between internalized receptor signaling and
MAPK activation has been demonstrated, the observation that LMW-PTP
does not act on Tyr(P)-716 supports our previous data about the
inability of LMW-PTP to affect the tyrosine phosphorylation level of
the internalized receptor (Fig. 2). In this light, it is likely that
LMW-PTP has an only apparent preference for cell surface receptors, due
to real receptor phosphotyrosine recognition. In agreement with these
data, we demonstrated that LMW-PTP influences the activation of many
signal transduction pathways such as PI3K, SHP-2, and PLC- LMW-PTP down-regulatory activity on PDGF-r might be controlled by
several physiological conditions. In particular, we observed an
increase of both the amount (by translational control) and activity (by
redox regulation) of LMW-PTP by cell growth arrest stimuli, as
cell-cell contact and cell differentiation. In both these situations,
we demonstrated an increased down-regulation of PDGF-r (43). The
regulated activity and expression of several PTPs might be a mechanism
whereby receptors with various levels and/or patterns of tyrosine
phosphorylation and concomitant variations in the pattern of associated
SH2 domain-containing proteins and signaling output could be generated.
Additional studies on PTP-dependent variations in the
tyrosine phosphorylation level and/or pattern of the PDGF-r and other
receptor tyrosine kinases in cells grown under various culture
conditions, as well as in intact tissues, are therefore highly warranted.
1 binding but not of MAPK activation. In addition, we report a slight action of LMW-PTP on
Tyr-716, which directs MAPK activation through Grb2 binding. On the
basis of these results, we propose a key role for LMW-PTP in PDGF-r
down-regulation through the dephosphorylation of the activation loop
Tyr-857, thus determining a general negative regulation of all
downstream signals, with the exception of those elicited by
internalized receptors.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-r mRNA expression.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(20). Immunoprecipitates were incubated in the presence of 20 mM
1,4-piperazinediethanesulfonic acid, pH 7.0, 10 mM
MnCl2, 20 µg/ml aprotinin, and 10 µCi of
[
-32-P]ATP (3000 Ci/mmol) for 10 min at 30 °C in
the presence or absence of 0.5 µg of glutathione
S-transferase-PLC-
1. The fusion protein included amino
acid residues 550-850 of rat PLC-
1. The reaction was stopped by
adding an equal volume of 2× sample buffer (10 mM EDTA,
4% SDS, 5.6 mM 2-mercaptoethanol, 20% glycerol, 200 mM Tris-HCl, pH 6.8, and 1% bromphenol blue). The samples
were then incubated for 3 min at 95 °C, spun, and resolved on 7.5%
SDS-polyacrylamide gel electrophoresis, and the radiolabeled proteins
were detected by autoradiography. Normalization has been achieved by
anti-PLC-
1 immunoblot of a part of the analyzed samples.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (25K):
[in a new window]
Fig. 1.
LMW-PTP controls PDGF-r tyrosine
phosphorylation level. 1 × 106 dnLMW-PTP or
mock-transfected NIH3T3 cells were serum-starved for 24 h and then
stimulated with 30 ng/ml PDGF-BB for the indicated periods.
A, PDGF-r was immunoprecipitated from lysates, and the
anti-phosphotyrosine immunoblot was performed. B, the
blot was stripped and reprobed with anti-PDGF-r antibodies. Data have
been analyzed by Chemidoc Quantity One software, and the normalized
values obtained are plotted in C (n = 5).

View larger version (26K):
[in a new window]
Fig. 2.
LMW-PTP does not affect the tyrosine
phosphorylation of the internalized PDGF-r. 1 × 106 dnLMW-PTP or mock-transfected NIH3T3 cells were
serum-starved for 24 h and then stimulated with 30 ng/ml PDGF-BB
for the indicated periods. PDGF-r internalization was evaluated by
trypsin treatment as reported under "Experimental Procedures."
A, PDGF-r was immunoprecipitated from lysates, and an
anti-phosphotyrosine immunoblot was performed. B, the blot
was stripped and reprobed with anti-PDGF-r antibodies. Data have been
analyzed by Chemidoc Quantitation Analysis software, and the normalized
data values obtained are plotted in C (n = 4).
receptor or the Y857F mutant were stimulated with
PDGF-BB, and the binding of dnLMW-PTP to agarose-bound activated PDGF-r
was analyzed (Fig. 3A).
Receptor activation in cells expressing either wild-type or mutant
PDGF-r was checked by antiphosphotyrosine immunoblot of the
agarose-bound receptors (Fig. 3B). The results show that the
association between PDGF-r and LMW-PTP is dramatically reduced in cells
expressing the Y857F mutant of PDGF-r compared with cells
expressing the wild-type receptor, suggesting that Tyr-857 is a key
binding site for LMW-PTP in the activated receptor. In addition, we
analyzed the phosphorylation level of this residue by means of
anti-phospho-Y857 antibodies (Fig. 3C). PDGF-r content has
been checked by anti-PDGF-r immunoblot of the stripped blot (Fig.
3D). The results indicate that phosphorylation of tyrosine
857, although transient, is dramatically increased by dnLMW-PTP
overexpression. LMW-PTP appears to influence only the phosphorylation
level of Tyr-857 in the maximum peak (namely, 10 min after PDGF
stimulation), and does not appear to influence the temporal extent of
its phosphorylation.

View larger version (37K):
[in a new window]
Fig. 3.
LMW-PTP binds and dephosphorylates Tyr-857 in
the PDGF-r. A, LMW-PTP in vitro binding
assay. After PDGF-BB stimulation, HepG2 cells were lysed, and PDGF-r
was immunoprecipitated. Immunocomplexes were collected, washed several
times, and allowed to associate with 1 µg of glutathione
S-transferase-LMW-PTP. The beads were washed and resuspended
in SDS-PAGE sample buffer for anti-LMW-PTP immunoblot analysis. The
activation of PDGF-r in the experiment was checked by
anti-phosphotyrosine immunoblot of part of the same samples
(B). The experiment is representative of three independent
repetitions. C, tyrosine phosphorylation of Tyr-857. 1 × 106 dnLMW-PTP or mock-transfected NIH3T3 cells were
stimulated with 30 ng/ml PDGF-BB for the indicated times. PDGF-r was
immunoprecipitated from lysates, and an anti-phospho-Tyr-857 immunoblot
was performed. Equalization was checked by stripping the blot and
reprobing with anti-PDGF-r antibodies. D, the blot was
stripped and reprobed with anti-PDGF-r antibodies. The results are the
mean of at least three experiments.
1 was monitored under
the same experimental conditions (Fig. 4B), obtaining
results in agreement with the PDGF-r autophosphorylation assay. The
results of the normalized data (Fig. 4, A and B)
show that dnLMW-PTP overexpression affects receptor kinase activity
only at 10 min, and not at longer times. It has been proposed that the
phosphorylation of the different tyrosines in PDGF-r display temporal
and spatial distribution, suggesting that receptor functions
corresponding to each of the phosphorylated sites were regulated as a
function of time. In particular, Bernard and Kazlauskas (17)
propose that whereas the kinase activity of the receptor is regulated
within the first 10 min after stimulation, other receptor functions
persist for longer times. It is likely that LMW-PTP affects receptor
kinase activity only at 10 min because the phosphorylation of tyrosine 857, which is required for activation of receptor kinase activity, is
present only within that 10-min period.

View larger version (31K):
[in a new window]
Fig. 4.
LMW-PTP affects the kinase activity of
PDGF-r. A and B, 1 × 106
dnLMW-PTP or mock-transfected NIH3T3 cells were serum-starved for
24 h and then stimulated with 30 ng/ml PDGF-BB. PDGF-r was
immunoprecipitated from lysates, and an immunokinase assay was
performed as reported under "Experimental Procedures." PDGF-r
autophosphorylation kinase activity is reported in A, and
PDGF-r kinase activity toward glutathione
S-transferase-PLC-
1 is reported in B. The
ratio between the densitometric analyses of kinase assays and of
normalization blots (anti-PDGF-r or anti-PLC-
1 immunoblots) is shown
in both A and B (n = 3).
1 binding
site). The results in Fig. 5
show that dnLMW-PTP appears to greatly increase the tyrosine
phosphorylation level of Tyr-857 (Fig. 5A) and Tyr-751 (Fig.
5B) and partially increase that of Tyr-1021 (Fig.
5C). On the contrary, the effect on Tyr-716 (Fig.
5D) is absent, in agreement with our previous observation
about the lack of dephosphorylation of internalized activated
receptors.

View larger version (48K):
[in a new window]
Fig. 5.
Analysis of the tyrosine phosphorylation
level of several PDGF-r sites. 1 × 106 dnLMW-PTP
or mock-transfected NIH3T3 cells were serum-starved for 24 h and
then stimulated with 30 ng/ml PDGF-BB for the indicated times. PDGF-r
was immunoprecipitated from lysates, and sequential Western blots were
performed. The ratios between the densitometric analyses of the
anti-phosphospecific immunoblots and the anti-PDGF-r blots have been
plotted and reported in each panel. A, anti-Tyr(P)-857
phosphorylation. B, anti-Tyr(P)-751 phosphorylation.
C, anti-Tyr(P)-1021 phosphorylation. D,
anti-Tyr(P)-716 phosphorylation. E, the blot has been
stripped several times for each phosphospecific antibody and finally
reprobed with anti-PDGF-r antibodies for normalization. These data are
representative of at least three independent experiments with similar
results.
1 binds to Tyr-1021, and SHP-2
binds to Tyr-1009 (3, 31). Because the ability of these proteins to
bind to the receptor is directly proportional to the phosphorylation of
the binding site, we analyzed the recruitment of many SH2
domain-containing proteins to the receptor in mock-transfected and
dnLMW-PTP-expressing cells. Fig. 6 shows
the results obtained. dnLMW-PTP overexpression leads to increased
binding of PI3K (Fig. 6A), PLC-
1 (Fig. 6B),
and SHP-2 (Fig. 6C). In addition, to confirm the general
action of LMW-PTP on PDGF-r downstream signaling, we analyzed the
activity of PI3K and MAPK in a time course experiment in
dnLMW-PTP-expressing cells in comparison with mock-transfected cells.
dnLMW-PTP overexpression leads to enhanced PI3K activity in both the
immediate (10 min) and the tardive (5-8 h) waves of phosphoinositide
production, suggesting a role for tyrosine phosphorylation in both PI3K
activity waves (Fig. 6D). These data confirm a specific role
of LMW-PTP in the long-lasting PDGF-r tyrosine phosphorylation regulation. On the contrary, we do not find any variation of MAPK activation in dnLMW-PTP-overexpressing cells in comparison with mock-transfected cells (Fig. 6E). This finding is in
agreement with the lack of effect of dnLMW-PTP on Tyr-716
phosphorylation because this residue mediates the binding of Grb2 to
the activated receptor and hence the activation of the Ras/Raf/MAPK
pathway.

View larger version (32K):
[in a new window]
Fig. 6.
Analysis of PDGF-r downstream pathways
affected by LMW-PTP. 1 × 106 dnLMW-PTP or
mock-transfected NIH3T3 cells were serum-starved for 24 h and
then stimulated with 30 ng/ml PDGF-BB for the indicated times.
PDGF-r was immunoprecipitated from lysates, and sequential Western
blots were performed. A, anti-p85-PI3K immunoblot.
B, anti-PLC-
1 immunoblot. C, anti-SHP-2
immunoblot. These data are representative of at least three independent
experiments with similar results. D, 400 µg of total
proteins were used in a PI3K assay as reported under "Experimental
Procedures" (n = 5). E, 40 µg of total
proteins from lysates were used for an anti-phospho-MAPK immunoblot.
F, equalization was confirmed by stripping the blot and
reprobing with anti-MAPK antibodies. The results are representative of
at least three independent experiments.
1 recruitment may be due to a direct dephosphorylation of
the phosphotyrosines that begin these signals or may be a simple consequence of a down-regulation of the kinase activity of the receptor
through dephosphorylation of Tyr-857.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
in A431 cells
have been obtained by inducible overexpression of rPTP
and by
down-regulation of endogenous rPTP
expression levels with an
antisense approach (33). Receptor tyrosine kinase dephosphorylation by
PTPs can lead to two outcomes: complete abrogation of the signal through dephosphorylation of the regulatory tyrosine and/or through general dephosphorylation or, alternatively, selective modulation of
the signal output by dephosphorylation of a subset of SH2 domain or
phosphotyrosine binding (PTB) domain binding phosphotyrosines. There
are few reports concerning this feature. Kovalenko et al. (9) reported that a receptor-like PTP called
density-enhanced phosphatase-1 displays site selectivity
dephosphorylation of PDGF-r, preferring Tyr-763, Tyr-771, and Tyr-778
and not affecting the Tyr-857 regulatory site. Again, SHP-2
dephosphorylation of PDGF-r revealed preferential dephosphorylation of
Tyr-771, Tyr-751, and Tyr-750 (34), namely, the PI3K and Ras-GAP
binding sites. For both these phosphatases, the activation loop
regulatory Tyr-857 was not a preferential substrate, suggesting that
both SHP-2 and density-enhanced phosphatase-1 could be modulators of
some signal transduction pathways, instead of general signal
termination enzymes.
1 binding
site). Although PDGF-r has many other tyrosines that can be
phosphorylated upon agonist stimulation, in this way we spanned all
functions of the activated receptor: (a) the relay of the
kinase activity of the receptor itself by Tyr-857, (b) the
activation of PI3K, the main mitogenic pathway starting from the
receptor, by Tyr-751, (c) the activation of MAPK pathway by
Tyr-716, through the Grb2/Sos/Ras/Raf/Mek route, which is mediated
mainly by the internalized PDGF-r, and (d) the activation of
PLC-
1 by Tyr-1021. We show that LMW-PTP influences the tyrosine
phosphorylation level of Tyr-857and Tyr-751 and partially influences
that of Tyr-1021 (Fig. 5).
1 but not
of MAPK (Fig. 6), confirming the silencing of many, but not all,
phosphotyrosines. Taken together, these data suggest that
LMW-PTP acts as a general PDGF-r signaling terminator
enzyme by dephosphorylating the regulatory Tyr-857 and many of the
phosphotyrosines that mediated SH2-binding protein activation, such as
PI3K, PLC-
1, and SHP-2. The action of LMW-PTP on SH2 binding
phosphotyrosines may be a direct dephosphorylation or a consequence of
a down-regulation of the kinase activity of the receptor through
dephosphorylation of Tyr-857. Our data on the selective binding of
LMW-PTP of Tyr-857 appear to strengthen the second of these hypotheses.
| |
ACKNOWLEDGEMENT |
|---|
We thank Dr. A. Kazlauskas for anti-Tyr(P)-857 and anti-Tyr(P)-751 antibodies and for HepG2 cells expressing wild-type and Y857F PDGF-r.
| |
FOOTNOTES |
|---|
* This work was supported in part by Consiglio Nazionale delle Ricerche (target project on Biotechnology, Strategic project "Controlli post-trascrizionali dell'espressione genica"), the Italian Association for Cancer Research, the Ministero della Università e Ricerca Scientifica e Tecnologica (MIUR-PRIN 2000 and MIUR-Consiglio Nazionale delle Ricerche Biotechnology program L.95/95), and Cassa di Risparmio di Firenze.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biochemical
Sciences, University of Florence, viale Morgagni 50, 50134 Florence,
Italy. Tel.: 39-055-413765; Fax: 39-055-4222725; E-mail: raugei@scibio.unifi.it.
Published, JBC Papers in Press, July 30, 2002, DOI 10.1074/jbc.M205203200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
PDGF, platelet-derived growth factor;
PDGF-r, PDGF receptor;
PI3K, phosphatidylinositol 3-kinase;
PLC-
1, phospholipase C-
1;
PTP, phosphotyrosine phosphatase;
LMW-PTP, low molecular weight PTP;
dnLMW-PTP, dominant negative LMW-PTP;
SHP, Src homology phosphatase;
MAPK, mitogen-activated protein kinase;
SH2, Src homology 2.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Schlessinger, J. (2000) Cell 103, 211-225[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Hubbard, S. R., and Till, J. H. (2000) Annu. Rev. Biochem. 69, 373-398[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Heldin, C. H., Ostman, A., and Ronnstrand, L. (1998) Biochim. Biophys. Acta 1378, F79-F113[Medline] [Order article via Infotrieve] |
| 4. |
Joazeiro, C. A.,
Wing, S. S.,
Huang, H.,
Leverson, J. D.,
Hunter, T.,
and Liu, Y. C.
(1999)
Science
286,
309-312 |
| 5. |
Jallal, B.,
Schlessinger, J.,
and Ullrich, A.
(1992)
J. Biol. Chem.
267,
4357-4363 |
| 6. |
Sorby, M.,
and Ostman, A.
(1996)
J. Biol. Chem.
271,
10963-10966 |
| 7. | Ostman, A., and Bohmer, F. D. (2001) Trends Cell Biol. 11, 258-266[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Qi, J. H.,
Ito, N.,
and Claesson-Welsh, L.
(1999)
J. Biol. Chem.
274,
14455-14463 |
| 9. |
Kovalenko, M.,
Denner, K.,
Sandstrom, J.,
Persson, C.,
Gross, S.,
Jandt, E.,
Vilella, R.,
Bohmer, F.,
and Ostman, A.
(2000)
J. Biol. Chem.
275,
16219-16226 |
| 10. | Chiarugi, P., Cirri, P., Raugei, G., Camici, G., Dolfi, F., Berti, A., and Ramponi, G. (1995) FEBS Lett. 372, 49-53[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Way, B. A.,
and Mooney, R. A.
(1993)
J. Biol. Chem.
268,
26409-26415 |
| 12. |
Chiarugi, P.,
Fiaschi, T.,
Taddei, M. L.,
Talini, D.,
Giannoni, E.,
Raugei, G.,
and Ramponi, G.
(2001)
J. Biol. Chem.
276,
33478-33487 |
| 13. |
Chiarugi, P.,
Cirri, P.,
Marra, F.,
Raugei, G.,
Fiaschi, T.,
Camici, G.,
Manao, G.,
Romanelli, R. G.,
and Ramponi, G.
(1998)
J. Biol. Chem.
273,
6776-6785 |
| 14. |
Cirri, P.,
Chiarugi, P.,
Taddei, L.,
Raugei, G.,
Camici, G.,
Manao, G.,
and Ramponi, G.
(1998)
J. Biol. Chem.
273,
32522-32527 |
| 15. |
Chiarugi, P.,
Cirri, P.,
Taddei, L.,
Giannoni, E.,
Camici, G.,
Manao, G.,
Raugei, G.,
and Ramponi, G.
(2000)
J. Biol. Chem.
275,
4640-4646 |
| 16. |
Baxter, R. M.,
Secrist, J. P.,
Vaillancourt, R. R.,
and Kazlauskas, A.
(1998)
J. Biol. Chem.
273,
17050-17055 |
| 17. | Bernard, A., and Kazlauskas, A. (1999) Exp. Cell Res. 253, 704-712[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Ceresa, B. P.,
Kao, A. W.,
Santeler, S. R.,
and Pessin, J. E.
(1998)
Mol. Cell. Biol.
18,
3862-3870 |
| 19. | Sorkin, A., Eriksson, A., Heldin, C. H., Westermark, B., and Claesson-Welsh, L. (1993) J. Cell. Physiol. 156, 373-382[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
DeMali, K. A.,
Whiteford, C. C.,
Ulug, E. T.,
and Kazlauskas, A.
(1997)
J. Biol. Chem.
272,
9011-9018 |
| 21. | Marra, F., Pinzani, M., DeFranco, R., Laffi, G., and Gentilini, P. (1995) FEBS Lett. 376, 141-145[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Deleted in proof |
| 23. | Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18, 2714-2723[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Berti, A., Rigacci, S., Raugei, G., Degl'Innocenti, D., and Ramponi, G. (1994) FEBS Lett. 349, 7-12[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Leof, E. B. (2000) Trends Cell Biol. 10, 343-348[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Burke, P.,
Schooler, K.,
and Wiley, H. S.
(2001)
Mol. Biol. Cell
12,
1897-1910 |
| 27. |
Kranenburg, O.,
Verlaan, I.,
and Moolenaar, W. H.
(1999)
J. Biol. Chem.
274,
35301-35304 |
| 28. |
Vieira, A. V.,
Lamaze, C.,
and Schmid, S. L.
(1996)
Science
274,
2086-2089 |
| 29. | Jones, S. M., and Kazlauskas, A. (2001) Nat. Cell Biol. 3, 165-172[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Fantl, W. J.,
Escobedo, J. A.,
and Williams, L. T.
(1989)
Mol. Cell. Biol.
9,
4473-4478 |
| 31. | Kazlauskas, A., Durden, D. L., and Cooper, J. A. (1991) Cell Regul. 2, 413-425[Medline] [Order article via Infotrieve] |
| 32. |
Claesson-Welsh, L.
(1994)
J. Biol. Chem.
269,
32023-32026 |
| 33. | Mooney, R. A., Kulas, D. T., Bleyle, L. A., and Novak, J. S. (1997) Biochem. Biophys. Res. Commun. 235, 709-712[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Graness, A., Hanke, S., Boehmer, F. D., Presek, P., and Liebmann, C. (2000) Biochem. J. 347, 441-447[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Klinghoffer, R. A.,
and Kazlauskas, A.
(1995)
J. Biol. Chem.
270,
22208-22217 |
| 36. |
Joly, M.,
Kazlauskas, A.,
and Corvera, S.
(1995)
J. Biol. Chem.
270,
13225-13230 |
| 37. |
Chow, J. C.,
Condorelli, G.,
and Smith, R. J.
(1998)
J. Biol. Chem.
273,
4672-4680 |
| 38. | Faure, R., Gaulin, J. F., Bourgoin, S., and Fortier, S. (1999) Mol. Cell Biol. Res. Commun. 1, 132-139[CrossRef][Medline] [Order article via Infotrieve] |
| 39. |
Chiarugi, P.,
Cirri, P.,
Taddei, M. L.,
Talini, D.,
Doria, L.,
Fiaschi, T.,
Buricchi, F.,
Giannoni, E.,
Camici, G.,
Raugei, G.,
and Ramponi, G.
(2002)
J. Cell Sci.
115,
2219-2232 |
| 40. | Jones, S. M., Klinghoffer, R., Prestwich, G. D., Toker, A., and Kazlauskas, A. (1999) Curr. Biol. 9, 512-521[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Kazlauskas, A., and Cooper, J. A. (1989) Cell 58, 1121-1133[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Arvidsson, A. K., Rupp, E., Nanberg, E., Downward, J., Ronnstrand, L., Wennstrom, S., Schlessinger, J., Heldin, C. H., and Claesson-Welsh, L. (1994) Mol. Cell. Biol. 10, 6715-6726 |
| 43. |
Fiaschi, T.,
Chiarugi, P.,
Buricchi, F.,
Giannoni, E.,
Taddei, M. L.,
Talini, D.,
Cozzi, G.,
Zecchi-Orlandini, S.,
Raugei, G.,
and Ramponi, G.
(2001)
J. Biol. Chem.
276,
49156-49163 |
This article has been cited by other articles:
![]() |
I. Pilecka, C. Patrignani, R. Pescini, M.-L. Curchod, D. Perrin, Y. Xue, J. Yasenchak, A. Clark, M. C. Magnone, P. Zaratin, et al. Protein-tyrosine Phosphatase H1 Controls Growth Hormone Receptor Signaling and Systemic Growth J. Biol. Chem., November 30, 2007; 282(48): 35405 - 35415. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Pandey, X. X. Yu, L. M. Watts, M. D. Michael, K. W. Sloop, A. R. Rivard, T. A. Leedom, V. P. Manchem, L. Samadzadeh, R. A. McKay, et al. Reduction of Low Molecular Weight Protein-tyrosine Phosphatase Expression Improves Hyperglycemia and Insulin Sensitivity in Obese Mice J. Biol. Chem., May 11, 2007; 282(19): 14291 - 14299. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Abraham, J. Schafer, M. Rothe, J. Bange, P. Knyazev, and A. Ullrich Identification of MMP-15 as an Anti-apoptotic Factor in Cancer Cells J. Biol. Chem., October 7, 2005; 280(40): 34123 - 34132. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kappert, K. G. Peters, F. D. Bohmer, and A. Ostman Tyrosine phosphatases in vessel wall signaling Cardiovasc Res, February 15, 2005; 65(3): 587 - 598. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Park, I. C. Schneider, and J. M. Haugh Kinetic Analysis of Platelet-derived Growth Factor Receptor/Phosphoinositide 3-Kinase/Akt Signaling in Fibroblasts J. Biol. Chem., September 26, 2003; 278(39): 37064 - 37072. [Abstract] [Full Text] [PDF] |
||||
| ||||||